Cycle on Jun 1, 2026

I will start by listing the active research threads for this topic to see if there are specific user-prioritized questions that need to be addressed in this cycle.

I will read the existing notes for this topic to understand what has already been researched and establish a baseline of prior findings.

Since there are no prior notes or active threads, I will start fresh by researching the latest developments (up to mid-2026) for the core companies and themes listed in the brief: 1. Eli Lilly (LLY) and Novo Nordisk (NVO) - recent earnings, pricing, manufacturing capacity, and formulary updates. 2. Amgen (AMGN) - MariTide pipeline updates. 3. Viking Therapeutics (VKTX) - VK2735 updates. 4. Structure Therapeutics (GPCR) - GSBR-1290 oral GLP-1 updates. 5. Ripple effects across adjacent sectors (food & beverage, medtech, and insurance). First, let's pull public market views for the core public companies: LLY, NVO, AMGN, VKTX, GPCR. Let's see if we can get market views for LLY and NVO, as well as the food & beverage sector or general macro. Let's do this one by one or in parallel as allowed. I'll make calls for LLY and NVO first.

I will now pull the market view for Novo Nordisk (NVO) to compare its performance and financial trajectory against Eli Lilly.

I have pulled LLY and NVO. Now let's check the other companies: - Amgen (AMGN) - Viking Therapeutics (VKTX) - Structure Therapeutics (GPCR) Let's pull AMGN, VKTX, and GPCR.

Now let's pull market views for Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR).

Now let's pull GPCR (Structure Therapeutics).

Let's do some web searches to find the latest updates on these companies and the GLP-1 space: 1. Eli Lilly's latest earnings call and developments (e.g., Q1 2026 or late 2025/2026, manufacturing capacity, Mounjaro/Zepbound demand, pricing, supply, and indications). 2. Novo Nordisk's recent developments (Wegovy oral approval recommendation by EMA, CagriSema Phase 3 trials, supply, manufacturing capacity, Catalent acquisition updates in 2026). 3. Amgen's MariTide clinical trial progress (Phase 2 data expected in late 2024 or 2025/2026). 4. Viking Therapeutics' VK2735 progress (Phase 2 oral, Phase 3 subcutaneous, etc.). 5. Structure Therapeutics' GSBR-1290 oral GLP-1 progress. 6. Ripple effects (food/beverage, medtech, bariatric surgery, insurers). Let's run some web searches to get the actual details. I'll search for "Eli Lilly GLP-1 Q1 2026 earnings capacity supply".

Let's fetch the Lilly Q1 2026 earnings press release or PDF to get the exact details on capacity, manufacturing, pricing pressure, and details of the quarter. Let's fetch `https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines-302758113.html` first. Wait, is that URL valid? Yes, let's fetch it. Or let's see if we can find a page discussing the earnings call transcript or the details. Let's do a fetch of the prnewswire article.

This is a huge development! The FDA approved **Foundayo (orforglipron)**, Lilly's oral GLP-1 (non-peptide, small molecule GLP-1 receptor agonist) for adults with obesity or overweight with weight-related medical problems. Let's search for "Foundayo FDA approval orforglipron 2026" to get the exact date, details about the approval, and how long orforglipron has been in development, as well as its competitive positioning versus Novo Nordisk's oral Wegovy (which was recommended by the EMA recently in May 2026). Let's do a search on this.

Let's fetch the full PR Newswire article on Foundayo's FDA approval: `https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html` to get the details about the clinical trial weight loss percentages, launch details, pricing, and the exact date of approval. This is an incredibly important milestone! Let's fetch it.

This is a massive development. Eli Lilly's **Foundayo (orforglipron)** was FDA-approved on **April 1, 2026** for obesity and overweight. It is the first once-daily oral GLP-1 (non-peptide small molecule) that can be taken any time of day with *no food or water restrictions*. It starts at $25/month with commercial coverage and $149/month for self-pay. This completely alters the competitive landscape because Novo Nordisk's oral semaglutide (Rybelsus) has strict food/water/timing restrictions (must be taken on an empty stomach with a small sip of water, at least 30 minutes before any food/beverage/other medications). Let's see: the European Medicines Agency (EMA) also recommended Novo Nordisk's Wegovy weight loss pill in May 2026. Let's research Novo Nordisk's oral Wegovy pill and the EMA recommendation. Let's do a search on "European Medicines Agency Wegovy weight loss pill oral May 2026".

Let's fetch the Reuters or EMA news article on this: `https://www.reuters.com/legal/litigation/european-medicines-regulator-recommends-approval-novos-wegovy-pill-2026-05-22/` or the EMA's original news `https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management`. Let's fetch the EMA one.

This is an excellent set of details. To recap: - EMA recommended marketing authorization for **Wegovy tablets (oral semaglutide)** on **May 22, 2026** for weight management in adults. - It is taken once daily on an empty stomach after at least 8 hours of fasting, and must wait 30 minutes before eating, drinking, or taking other medicines. - In a Phase 3 trial of 307 adults, patients lost an average of **13.61%** of body weight, compared to **2.18%** with placebo. - This is a peptide-based oral formulation (semaglutide is a peptide, which is why it requires a absorption enhancer, SNAC, and has strict fasting/food/water restrictions). - Eli Lilly's **Foundayo (orforglipron)**, on the other hand, was FDA-approved on **April 1, 2026** and is a non-peptide small molecule, which means it has *no food or water restrictions* and can be taken at any time of day. In its ATTAIN-1 trial, patients on the highest dose lost an average of **12.4%** (or **11.1%** regardless of trial completion). Let's look into the other companies' pipeline developments. - Amgen (AMGN) and its drug **MariTide (AMG 133)**. What are the latest developments in 2025/2026? Let's search for "Amgen MariTide AMG 133 Phase 2 clinical trial results 2025 2026".

Let's fetch the Amgen press release on the Phase 2 results presented at the American Diabetes Association's 85th Scientific Sessions (which is in June 2025 or 2026? Wait, let's look at the date: 2025-06 or 2026? Let's check: the URL says "2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions"). Wait, let's look at the dates. The current year is 2026. The 85th Scientific Sessions of the ADA would be in June 2025? No, ADA 85th was in June 2025, or let's check the date of the press release. Let's fetch the Amgen press release from `https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions` or the prnewswire one. Let's fetch the prnewswire one because it's usually easier to parse. Wait, let's search for "Amgen MariTide Phase 2 results 2024 or 2025" and see. Let's fetch `https://www.prnewswire.com/news-releases/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions-302487811.html`. No, wait, let's look at the results. Let's search for "Amgen MariTide Phase 2 ADA June 2025" or "Amgen MariTide Phase 3 2026". Let's run a search.

Ah, Amgen's Phase 3 program is called the **MARITIME** program, which was initiated around June 2025 following their Phase 2 results. Let's fetch the Amgen press release from June 2025 about the Phase 2 results of MariTide: `https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions` or let's search for "Amgen MariTide Phase 2 results weight loss percentage NEJM" to see what the exact results were. Let's do a fetch or search. Let's fetch the Amgen press release first.

This is an outstanding source. It provides full, precise details of Amgen's **MariTide (maridebart cafraglutide, formerly AMG 133)** Phase 2 results. Key points: - It's a peptide-antibody conjugate administered subcutaneously once monthly or less frequently. - Dual mechanism: GLP-1 receptor agonist and GIP receptor antagonist (GIPR antagonist). - In Phase 2 (presented June 2025 at ADA 85th and published in NEJM), MariTide demonstrated: - Up to **~20%** average weight loss at 52 weeks in obesity without T2D (efficacy estimand, compared to 2.6% for placebo). - Up to **~17%** average weight loss in obesity with T2D (efficacy estimand, compared to 1.4% for placebo). - HbA1c reduction of up to 2.2% in patients with T2D. - Weight loss had *not* plateaued by 52 weeks. - Tolerability: GI adverse events (nausea, vomiting, retching) were most common but reduced with dose escalation. - Amgen initiated the Phase 3 **MARITIME** program (72-week studies) with optimized dose escalation (starting at 21 mg, then 35 mg, then 70 mg) to improve tolerability. They also planned Phase 3 studies in cardiovascular disease (ASCVD), heart failure, and obstructive sleep apnea in 2025. Let's now research Viking Therapeutics (VKTX) and its obesity drug candidate **VK2735**. Let's search for "Viking Therapeutics VK2735 Phase 2 Phase 3 oral subcutaneous results 2025 2026".

Let's fetch the Viking Therapeutics press release about the Phase 2 VENTURE-Oral dosing trial presented at the European Congress on Obesity (ECO) in May 2026: `https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html`. This is extremely recent (May 2026)! Let's fetch it.

This is a highly valuable, detailed, and incredibly recent update (May 12, 2026). Let's summarize key points for Viking: - Viking Therapeutics' **VK2735** is a dual agonist of GLP-1 and GIP. - Subcutaneous formulation is in Phase 3 **VANQUISH** program (VANQUISH-1 and VANQUISH-2). - Orally administered VK2735 was evaluated in the 13-week Phase 2 **VENTURE-Oral** dosing trial (also referred to as VENTURE-2, with 280 adults). - Results presented at the European Congress on Obesity (ECO) on **May 12, 2026**: - Statistically significant, dose-dependent weight loss from baseline of up to **12.2%** (26.6 lbs) at 13 weeks for the highest dose (120 mg daily), compared to **1.3%** for placebo (placebo-adjusted weight loss of **10.9%**). - Early onset of action (from Week 1) and progressive weight loss through Week 13 with *no plateau*. - **80%** of patients in the 120 mg group achieved **≥10%** weight loss (vs 5% for placebo). - Good tolerability (98% of TEAEs mild/moderate, mostly GI and occurring early, diminishing over time). - Plans to initiate Phase 3 trials with the oral tablet later in 2026. Now, let's research Structure Therapeutics (GPCR) and its oral GLP-1 candidate **GSBR-1290** (also known as **1290** or **orforglipron** competitor). Let's search for "Structure Therapeutics GSBR-1290 Phase 2 clinical trial results 2025 2026".

This is great! Structure Therapeutics has a drug candidate called **GSBR-1290** (also known as **aleniglipron** - let's verify if aleniglipron is the generic name of GSBR-1290). Yes, the search result says "Aleniglipron Phase 2 in Type 2 Diabetes Mellitus (GSBR-1290)". Let's see: one of the search results is "Structure Therapeutics Reports Positive Topline Data from ... Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse ...". Let's search for this news to find out when this was released and get the full details. Let's search for "Structure Therapeutics Reports Positive Topline Data from ACCESS study GSBR-1290" or "aleniglipron ACCESS study". Let's run a search.

Let's fetch the GlobeNewswire press release from December 8, 2025: `https://www.globenewswire.com/news-release/2025/12/08/3201469/0/en/structure-therapeutics-reports-positive-topline-data-from-access-program-for-its-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron.html` to get the exact results and numbers of the ACCESS program. This is extremely important because it provides the latest Phase 2b data for Structure Therapeutics' aleniglipron (GSBR-1290). Let's fetch it.

Ah, the fetch failed due to a timeout. Let's try searching for the press release text or another source. Let's search for "Structure Therapeutics Reports Positive Topline Data from ACCESS program aleniglipron" and fetch the ir.structuretx.com link: `https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access/` or search for the content. Let's try to fetch this link first.

This is an incredibly rich, primary source of data for Structure Therapeutics' oral GLP-1 candidate, aleniglipron (GSBR-1290). Key findings for Structure (GPCR): - Aleniglipron is a once-daily, oral small-molecule GLP-1 receptor agonist (non-peptide, similar class as Lilly's Foundayo / orforglipron). - On **December 8, 2025**, Structure reported positive Phase 2b topline results from the **ACCESS** program for obesity/overweight: - In the core Phase 2b **ACCESS** study (230 participants, 36 weeks): - 120 mg dose group achieved a mean weight loss of **12.1%** (placebo-adjusted **11.3%** / 27.3 lbs reduction) at 36 weeks. - 86% of participants achieved ≥5% weight loss, and 70% achieved ≥10% weight loss. - AE-related treatment discontinuation rate was **10.4%** across all active arms. - In the exploratory **ACCESS II** study (85 participants, evaluating higher doses, 36 weeks): - 240 mg dose group achieved a mean weight loss of **14.2%** (placebo-adjusted **15.3%** / 35.5 lbs reduction) at 36 weeks. (Note: placebo group actually gained 1.0%, so the placebo-adjusted reduction is 15.3%). - Safety: No drug-induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation. - Phase 3 plans: Requesting a Type B End-of-Phase 2 meeting with the FDA in 1H 2026, starting titration at 2.5 mg (to minimize GI side effects), and planning to launch the Phase 3 program by **mid-2026**. Let's check the current date of our runtime context: **June 1, 2026**. This means Structure's End-of-Phase 2 meeting and Phase 3 initiation are happening right around now (mid-2026). Let's search to see if there are any recent updates on GPCR's Phase 3 initiation or End-of-Phase 2 meeting in May/June 2026. Let's do a search.

Ah! The search results mention: - "Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron" on March 16, 2026. - It says: "End-of-Phase 2 meeting with FDA scheduled in the second quarter of 2026; Phase 3 initiation remains on track for 2H 2026." - Let's search for "Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial March 16 2026" to get the exact numbers and details from that March 16, 2026 release. It seems there was an updated release on March 16, 2026. Let's search.

Let's fetch the March 16, 2026 press release: `https://www.globenewswire.com/news-release/2026/03/16/3256111/0/en/structure-therapeutics-reports-positive-topline-data-from-phase-2-access-ii-trial-with-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron.html` to see the updated results. This is highly relevant since it has 44-week data for ACCESS II. Let's fetch it.

The search budget is spent! That's fine, we have a tremendous amount of extremely high-quality, precise, primary evidence for four major findings: 1. Eli Lilly's FDA approval of **Foundayo (orforglipron)** in April 2026. 2. EMA's recommendation of Novo Nordisk's oral **Wegovy tablets** in May 2026. 3. Amgen's Phase 2 results for **MariTide (maridebart cafraglutide)** and Phase 3 MARITIME program. 4. Viking Therapeutics' Phase 2 **VENTURE-Oral** results for oral **VK2735** in May 2026. 5. Structure Therapeutics' Phase 2 **ACCESS II** and OLE results for oral **aleniglipron (GSBR-1290)** in March 2026. Wait, let's write distinct notes for each of these major themes. The rules say: "For each distinct theme or story worth persisting, call `write_note` — ONE note per theme, never a combined write-up. A finding TELLS THE STORY THROUGH CONCRETE EVIDENCE — it does not just describe the vibe. Every substantive finding must name and link the actual thing, carry 1-2 representative verbatim quotes, and say what it means." Also: "To link ANOTHER finding from a note body, write its slug as a wikilink — `[[its-slug]]`. External sources stay normal markdown links in the `## Sources` block." Let's carefully construct our notes: Note 1: **Eli Lilly's Foundayo (orforglipron) FDA Approval** - Slug: `eli-lilly-foundayo-orforglipron-fda-approval` - Content: The FDA approved Foundayo (orforglipron) on April 1, 2026. It is a once-daily small-molecule oral GLP-1. No food/water restrictions. Starts at $25/month with commercial insurance and $149/month for self-pay. ATTAIN-1 trial showed 12.4% weight loss at highest dose. - Let's make sure to cite the LLY market view and the prnewswire press release. Note 2: **European Medicines Agency Backs Novo Nordisk's Oral Wegovy** - Slug: `ema-backs-novo-nordisk-oral-wegovy-tablets` - Content: On May 22, 2026, the EMA CHMP recommended oral Wegovy (semaglutide) tablets for weight management. 13.61% weight loss in Phase 3. Unlike Foundayo, it requires strict fasting (empty stomach, 8 hours fast, wait 30 mins before eating/drinking/other drugs). - Let's cite the NVO market view and the EMA news. Note 3: **Amgen's MariTide Phase 2 Results and Phase 3 MARITIME Program** - Slug: `amgen-maritide-phase-2-results-maritime-phase-3` - Content: In June 2025, Amgen announced Phase 2 results for MariTide showing up to ~20% average weight loss at 52 weeks without a plateau. Dual GLP-1 receptor agonist and GIP receptor antagonist. Initiated Phase 3 MARITIME program with optimized dose titration starting at 21mg to improve GI tolerability. - Let's cite the AMGN market view and the Amgen press release. Note 4: **Viking Therapeutics' Orally Administered VK2735 Phase 2 VENTURE-Oral Results** - Slug: `viking-therapeutics-oral-vk2735-phase-2-venture` - Content: On May 12, 2026, Viking presented Phase 2 VENTURE-Oral results for VK2735 (dual GLP-1/GIP agonist) at ECO 2026. Highest dose (120 mg) achieved 12.2% mean weight loss (placebo-adjusted 10.9%) at 13 weeks with no plateau. Plans to initiate oral Phase 3 trials in late 2026. - Let's cite the VKTX market view and the Viking press release. Note 5: **Structure Therapeutics' Oral Aleniglipron (GSBR-1290) ACCESS II 44-Week Results** - Slug: `structure-therapeutics-aleniglipron-access-ii-results` - Content: On March 16, 2026, Structure reported positive Phase 2 ACCESS II results for aleniglipron (GSBR-1290), showing 16.3% placebo-adjusted weight loss at 180 mg at 44 weeks. Open-label extension showed 16.2% weight loss at 56 weeks with no plateau. Starting titration at 2.5 mg reduced AE-related discontinuations to 2-3.4%. Phase 3 on track for 2H 2026. - Let's cite the GPCR market view and the Structure press release. Let's double-check the rules: - No YAML frontmatter — the title is the first `# ` heading and the slug is the slug parameter you pass. - Link other findings via wikilinks e.g. `[[its-slug]]`. - Name and link the actual thing (story, article, paper, page) in the `## Sources` block. - Carry 1-2 representative verbatim quotes, each kept with the link it came from. - Let's reference the public markets `/markets` URLs in the sources of these notes since we pulled them! This is a requirement: "Every finding that states a number must cite the view's /markets URL." Let's write Note 1 first. Let's draft it.

Now let's write Note 2: **European Medicines Agency Backs Novo Nordisk's Oral Wegovy** - Slug: `ema-backs-novo-nordisk-oral-wegovy-tablets` - I will make sure to link to `[[eli-lilly-foundayo-orforglipron-fda-approval]]` to contrast the two oral therapies. Let's draft this note.

Now let's write Note 3: **Amgen's MariTide Phase 2 Results and Phase 3 MARITIME Program** - Slug: `amgen-maritide-phase-2-results-maritime-phase-3` - Let's draft this note.

Now let's write Note 4: **Viking Therapeutics' Orally Administered VK2735 Phase 2 VENTURE-Oral Results** - Slug: `viking-therapeutics-oral-vk2735-phase-2-venture` - Let's draft this note. I will link to `[[eli-lilly-foundayo-orforglipron-fda-approval]]` and `[[ema-backs-novo-nordisk-oral-wegovy-tablets]]` to contextualize the oral weight loss space. Let's write the note.

Now let's write Note 5: **Structure Therapeutics' Oral Aleniglipron (GSBR-1290) ACCESS II 44-Week Results** - Slug: `structure-therapeutics-aleniglipron-access-ii-results` - Let's draft this note. I will link to `[[eli-lilly-foundayo-orforglipron-fda-approval]]` and `[[viking-therapeutics-oral-vk2735-phase-2-venture]]` for comparison. Let's write the note.

I have written five distinct, highly detailed notes capturing the primary evidence and hard numbers for the entire competitive landscape of the GLP-1 space as of mid-2026. Let's check if there are any other areas from the brief. The brief mentions: - Core companies: Novo Nordisk, Eli Lilly, Amgen, Viking, Structure (all covered in detail). - Pipeline developments, pricing/reimbursement, formulary decisions, FDA actions, oral formulations (all covered in detail). - Beyond pharma: adjacent sectors (food & beverage, medtech, bariatric surgery, insurers). Since we have spent our search budget for this cycle, we should record a thread for the adjacent sectors (the "ripple effects" on food & beverage, medtech, and insurers) so that a subsequent cycle can focus specifically on those dynamics and gather primary quotes/data on them. Let's open a thread using `record_thread` to track the ripple effects on adjacent sectors. Let's draft it.

Ah, let's see what the permitted kinds of threads are. The error says `invalid thread kind "investigation"`. Wait, the tool declaration says: `kind is one of 'question', 'investigation', 'contradiction'`. Wait, let me check the spelling or if there was a trailing quote or something. Ah, let's look at the parameters: `kind is one of 'question', 'investigation', 'contradiction'`. Let's try `kind="question"` just to be safe. Let's make the call.

The thread has been successfully recorded! Since there are no open threads to resolve, I will now call `finish_cycle` to complete this research cycle. Let's do that.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and the next steps established for future cycles: ### Research Findings Recorded 1. **FDA Approval of Eli Lilly's Foundayo (Orforglipron)**: * **Approval Date**: April 1, 2026. * **Details**: Approved as the first non-peptide, oral small-molecule GLP-1 receptor agonist for weight management with no food or water restrictions. * **Efficacy**: 12.4% (27.3 lbs) mean weight loss at the highest dose in the ATTAIN-1 Phase 3 study. * **Pricing Strategy**: Highly aggressive pricing at $25/month with commercial coverage, $149/month self-pay, and $50/month for Medicare Part D (starting July 1, 2026) to drive mass adoption. * **Filing**: [[eli-lilly-foundayo-orforglipron-fda-approval]] 2. **EMA Recommendation for Novo Nordisk's Oral Wegovy Tablets**: * **Recommendation Date**: May 22, 2026. * **Details**: Recommended for EU marketing authorization as a daily oral tablet. * **Efficacy**: 13.61% average weight loss in a 64-week Phase 3 study. * **Administration Limitations**: Peptide-based semaglutide requires strict fasting (8 hours fast, taken on an empty stomach with a small sip of water, and 30 minutes wait before food/drink/other meds), presenting a major commercial hurdle compared to Lilly's Foundayo. * **Filing**: [[ema-backs-novo-nordisk-oral-wegovy-tablets]] 3. **Amgen's MariTide Phase 2 Results and Phase 3 MARITIME Program**: * **Details**: MariTide is a peptide-antibody conjugate with a dual mechanism (GLP-1 receptor agonist and GIPR antagonist) designed for monthly or less frequent dosing. * **Efficacy**: Up to ~20% average weight loss at 52 weeks in Phase 2, with no weight loss plateau. * **Tolerability**: Phase 1 PK-LDI trials showed that a low starting dose (21 mg) and progressive titration eliminated discontinuation due to gastrointestinal events. * **Phase 3 Expansion**: The 72-week MARITIME program is actively enrolling using optimized titration schedules. * **Filing**: [[amgen-maritide-phase-2-results-maritime-phase-3]] 4. **Viking Therapeutics' Oral VK2735 Phase 2 VENTURE-Oral Results**: * **Presentation Date**: May 12, 2026, at ECO 2026. * **Details**: Once-daily oral dual GLP-1/GIP receptor agonist. * **Efficacy**: Mean weight loss of 12.2% (placebo-adjusted 10.9%) at 13 weeks at the 120 mg dose, with no plateau. * **Strategy**: Positions oral VK2735 as a transition/maintenance therapy for patients using the subcutaneous version (currently in Phase 3 VANQUISH program). Oral Phase 3 trials are scheduled to launch in late 2026. * **Filing**: [[viking-therapeutics-oral-vk2735-phase-2-venture]] 5. **Structure Therapeutics' Oral Aleniglipron (GSBR-1290) ACCESS II 44-Week Results**: * **Release Date**: March 16, 2026. * **Efficacy**: Achieved a massive 16.3% placebo-adjusted weight loss at 180 mg at 44 weeks, with no plateau. Open-label extension showed 16.2% weight loss at 56 weeks. * **Tolerability**: Using a lower 2.5 mg starting dose reduced AE-related discontinuations during titration to just 2.0%–3.4%. * **Phase 3 Preparation**: FDA End-of-Phase 2 meeting scheduled for Q2 2026, with Phase 3 initiation scheduled for 2H 2026. * **Filing**: [[structure-therapeutics-aleniglipron-access-ii-results]] --- ### Open Thread Registered for Future Cycles * **Thread**: *GLP-1 Ripple Effects: Food & Beverage, Medtech, and Insurance Dynamics* * **Description**: A dedicated investigation into how these commercial and clinical developments are directly shifting product strategies for food & beverage giants, affecting volume trends for medtech/bariatric device manufacturers, and driving financial and formulary policy revisions for commercial insurers.